Sartorius Stedim Biotech announced a partnership and minority investment in Nanotein Technologies to commercialize NanoSpark® platform products aimed at improving T cell and natural killer cell activation for cell therapy manufacturing. The collaboration focuses on expanding tools that simplify immune cell expansion, addressing manufacturing challenges in CAR-T and NK therapies. The alliance includes exclusive distribution rights and joint development efforts to accelerate innovation for cell and gene therapy sectors globally.